ProMIS Neurosciences, Inc. (PMN)
| Market Cap | 93.17M +338.5% |
| Revenue (ttm) | n/a |
| Net Income | -40.62M |
| EPS | -13.36 |
| Shares Out | 8.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,416 |
| Open | 10.56 |
| Previous Close | 10.58 |
| Day's Range | 10.39 - 10.70 |
| 52-Week Range | 6.27 - 39.75 |
| Beta | -0.18 |
| Analysts | Strong Buy |
| Price Target | 26.50 (+155.05%) |
| Earnings Date | May 12, 2026 |
About PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting t... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for PMN stock is "Strong Buy." The 12-month stock price target is $26.5, which is an increase of 155.05% from the latest price.
News
ProMIS Neurosciences reports Q1 EPS ($1.26) vs. ($5.27) last year
Existing cash resources of $63.8M at quarter end are expected to fund planned operations through 2027, including the completion of the PRECISE-AD trial. “2026 has the potential to be a…
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Cambridge, Massachusetts, May 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therape...
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's dise...
ProMIS Neurosciences files $200M mixed securities shelf
17:24 EDT ProMIS Neurosciences (PMN) files $200M mixed securities shelf
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in ear...
ProMIS Neurosciences files to sell 13.83M common shares for holders
The company will not receive any of the proceeds from sales of its securities by the selling securityholders pursuant to this prospectus.
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)
Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disea...
ProMIS Neurosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Enrollment in a robust phase 1b Alzheimer's trial is complete, with interim and final data expected this year. The proprietary EpiSelect platform enables highly selective targeting of toxic oligomers, aiming for improved efficacy and safety. Strong financing and high retention support a pivotal year.
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's diseas...
Promis Neurosciences Inc trading resumes
09:38 EST Promis Neurosciences (PMN) Inc trading resumes
Promis Neurosciences Inc trading halted, volatility trading pause
09:33 EST Promis Neurosciences (PMN) Inc trading halted, volatility trading pause
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS' landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-...
ProMIS Neurosciences exceeds target enrollment in PRECISE-AD
ProMIS Neurosciences (PMN) announced completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial, evaluating PMN310, the Company’s lead therapeutic antibody candidate for the tr...
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's disease
ProMIS Neurosciences announces publication highlighting PMN310
ProMIS Neurosciences (PMN) announced a publication in the peer-reviewed journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. entitled, “Relationship between efficacy and pr...
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque
ProMIS Neurosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference
The conference highlighted progress in a phase I-B Alzheimer's trial, with enrollment on track and interim safety and biomarker data expected next year. The lead antibody targets toxic oligomers, aiming for superior safety and efficacy, and may advance rapidly to phase III if results are positive.
ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright
H.C. Wainwright adjusted the firm’s price target on ProMIS Neurosciences (PMN) to $18 from $4 and keeps a Buy rating on the shares following the reverse stock split. Published first…
ProMIS Neurosciences announces publication on plasma pTau in Alzheimer’s
ProMIS Neurosciences (PMN) announced a publication in the peer-reviewed journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. entitled, “Leveraging recent advances in plasma...
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trial ProMIS on track to leverage new plasma...
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's diseas...
Promis Neurosciences Inc trading halted, news pending
19:50 EST Promis Neurosciences (PMN) Inc trading halted, news pending
ProMIS Neurosciences announces 1-for-20 reverse stock split
ProMIS Neurosciences (PMN) board of directors has determined to effect a one-for-twenty-five reverse stock split of the Company’s common shares, no par value per share. The reverse stock split will…
ProMIS Neurosciences Announces Reverse Stock Split
Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) an...
ProMIS Neurosciences price target lowered to $5 from $6 at Guggenheim
Guggenheim analyst Eddie Hickman lowered the firm’s price target on ProMIS Neurosciences (PMN) to $5 from $6 and keeps a Buy rating on the shares. ProMIS Neurosciences’ Alzheimer’s candidate, PMN310,…